| Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. They make these discoveries using proprietary gene knockout technology which allows for modelling on a genome-wide scale, the effects on physiology that could be expected from prospective drugs directed against novel targets. They have advanced more than 70 knockout-validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. |